Cefotetan in the treatment of obstetric and gynecologic infections.
The efficacy, tolerance, and safety of cefotetan--a new 7-alpha-methoxy cephalosporin--was assessed in controlled and uncontrolled evaluations involving 131 evaluable patients hospitalized with obstetric and gynecologic infections. The 99% satisfactory clinical response rate obtained with this drug was equivalent to that obtained with either moxalactam or cefoxitin, yet the mean amount of cefotetan given was lower than that of the other two drugs. Cefotetan was well tolerated and produced no major adverse reactions. In this era of Diagnosis Related Groups and cost containment, the twice-daily dosage schedule of cefotetan is a decided cost benefit.
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D015313:Cefotetan; D002440:Cefoxitin / Q000627:therapeutic use; D002513:Cephamycins / Q000378:metabolism / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009070:Moxalactam / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000378:metabolism; D011897:Random Allocation
D002513:Cephamycins; D015313:Cefotetan; D002440:Cefoxitin; D009070:Moxalactam